A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ros and ceramide levels

Molecular Pharmacology

Volumn 79, Issue 3, 2011, Pages 368-380

  Park, Margaret A ^a   Hamed, Hossein A ^a   Mitchell, Clint ^a   Cruickshanks, Nichola ^a   Dash, Rupesh ^a   Allegood, Jeremy ^a   Dmitriev, Igor P ^c   Tye, Gary ^a   Ogretmen, Besim ^d   Spiegel, Sarah ^a   Yacoub, Adly ^a   Grant, Steven ^a,b   Curiel, David T ^c   Fisher, Paul B ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CALCIUM ION; CERAMIDE; FAS ANTIGEN; FENRETINIDE; FLICE INHIBITORY PROTEIN; INTERLEUKIN 24; PROCASPASE 8; REACTIVE OXYGEN METABOLITE; TANESPIMYCIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANIMALS; ARSENICALS; BENZOQUINONES; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CERAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKINS; KIDNEY NEOPLASMS; LACTAMS, MACROCYCLIC; MICE; MICE, NUDE; OXIDES; REACTIVE OXYGEN SPECIES; TRANSFECTION;

EID: 79951983754     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.069484     Document Type: Article

References (48)

1. Azad MB, Chen Y, and Gibson SB (2009) Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 11:777-790.
2. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S, and Grimm EA (2002) The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 168:6041-6046. (Pubitemid 34620018)
3. Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D, et al. (2005) Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 11:149-159. (Pubitemid 40012009)
4. Dash R, Dmitriev I, Su ZZ, Bhutia SK, Azab B, Vozhilla N, Yacoub A, Dent P, Curiel DT, Sarkar D, et al. (2010) Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad. 5/3) improves therapeutic efficacy in low CAR prostate cancer cells. Cancer Gene Ther 17:447-456.
5. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, and Grimm EA (2001) Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer 94:54-59. (Pubitemid 32801752)
6. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, and Grimm EA (2002) Loss of MDA-7 expression with progression of melanoma. J Clin Oncol 20:1069-1074. (Pubitemid 34141852)
7. Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, Grant S, Dent P, Curiel DT, Sarkar D, et al. (2009) Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther 8:391-400.
8. Eulitt PJ, Park MA, Hossein H, Cruikshanks N, Yang C, Dmitriev IP, Yacoub A, Curiel DT, Fisher PB, and Dent P (2010) Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. Cancer Biol Ther 10:1290-1305.
9. Fisher PB (2005) Is mda-7/IL-24 a "magic bullet" for cancer? Cancer Res 65:10128-10138.
10. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR, Curiel DT, and Dent P (2003) mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther 2:S23-S37.
11. Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, and Blute ML (2005) Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol 173:1893-1896. (Pubitemid 40675205)
12. Gopalan B, Litvak A, Sharma S, Mhashilkar AM, Chada S, and Ramesh R (2005) Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells. Cancer Res 65:3017-3024. (Pubitemid 40524577)
13. Greco A, Di Benedetto A, Howard CM, Kelly S, Nande R, Dementieva Y, Miranda M, Brunetti A, Salvatore M, Claudio L, et al. (2010) Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther 18:295-306.
14. Gupta P, Emdad L, Lebedeva IV, Sarkar D, Dent P, Curiel DT, Settleman J, and Fisher PB (2008) Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. J Cell Physiol 215:827-836. (Pubitemid 351632704)
15. Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L, Bachelor MA, Grant S, Curiel DT, Dent P, et al. (2006) mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 111:596-628. (Pubitemid 44118431)
16. Gupta P, Walter MR, Su ZZ, Lebedeva IV, Emdad L, Randolph A, Valerie K, Sarkar D, and Fisher PB (2006a) BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis. Cancer Res 66:8182-8191. (Pubitemid 44299186)
17. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, et al. (2009) Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325:1254-1257.
18. Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, Dmitriev IP, Lesniak MS, Shah K, Grant S, et al. (2010) Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther 18:1130-1142.
19. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, Kang D, Jiang H, Lin JJ, Alexandre D, et al. (2001) Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 20:7051-7063. (Pubitemid 33052197)
20. Ishizawa J, Yoshida S, Oya M, Mizuno R, Shinojima T, Marumo K, and Murai M (2004) Inhibition of the ubiquitin-proteasome pathway activates stress kinases and induces apoptosis in renal cancer cells. Int J Oncol 25:697-702.
21. Jiang H, Lin JJ, Su ZZ, Goldstein NI, and Fisher PB (1995) Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11:2477-2486. (Pubitemid 26023815)
22. Lai WL and Wong NS (2008) The PERK/eIF2 alpha signaling pathway of Unfolded Protein Response is essential for N-(4-hydroxyphenyl)retinamide (4HPR)-induced cytotoxicity in cancer cells. Exp Cell Res 314:1667-1682.
23. Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR, Liu SJ, Taher MM, Xiao R, et al. (2007a) mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (review). Int J Oncol 31:985-1007.
24. Lebedeva IV, Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Gupta P, Nemunaitis J, Cunningham C, Yacoub A, Dent P, et al. (2005) mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther 11:4-18. (Pubitemid 40011994)
25. Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC, and Fisher PB (2002) The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 21:708-718. (Pubitemid 34146283)
26. Lebedeva IV, Su ZZ, Sarkar D, Gopalkrishnan RV, Waxman S, Yacoub A, Dent P, and Fisher PB (2005a) Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Oncogene 24:585-596. (Pubitemid 40188563)
27. Lebedeva IV, Washington I, Sarkar D, Clark JA, Fine RL, Dent P, Curiel DT, Turro NJ, and Fisher PB (2007b) Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Proc Natl Acad Sci USA 104:3484-3489. (Pubitemid 46364185)
28. Mitchell C, Park MA, Zhang G, Han SI, Harada H, Franklin RA, Yacoub A, Li PL, Hylemon PB, Grant S, et al. (2007) 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines. Mol Cancer Ther 6:618-632. (Pubitemid 46335554)
29. 2+-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 70:6313-6324.
30. Park MA, Walker T, Martin AP, Allegood J, Vozhilla N, Emdad L, Sarkar D, Rahmani M, Graf M, Yacoub A, et al. (2009) MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer Ther 8:1280-1291.
31. Park MA, Zhang G, Mitchell C, Rahmani M, Hamed H, Hagan MP, Yacoub A, Curiel DT, Fisher PB, Grant S, et al. (2008) Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther 7:2633-2648.
32. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, Brandt C, Jelinek L, Madden K, McKernan PA, et al. (2002) Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 277:47517-47523. (Pubitemid 36159270)
33. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, and Fisher PB (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22:929-979. (Pubitemid 38680445)
34. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K, Dent P, and Fisher PB (2002) mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA 99:10054-10059. (Pubitemid 34831171)
35. Sauane M, Gopalkrishnan RV, Choo HT, Gupta P, Lebedeva IV, Yacoub A, Dent P, and Fisher PB (2004a) Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analysed via a bacterial fusion protein. Oncogene 23:7679-7690. (Pubitemid 39424926)
36. Sauane M, Lebedeva IV, Su ZZ, Choo HT, Randolph A, Valerie K, Dent P, Gopalkrishnan RV, and Fisher PB (2004b) Melanoma differentiation associated gene-7/interleukin-24 promotes tumor cell-specific apoptosis through both secretory and nonsecretory pathways. Cancer Res 64:2988-2993. (Pubitemid 38581393)
37. Sauane M, Su ZZ, Dash R, Liu X, Norris JS, Sarkar D, Lee SG, Allegood JC, Dent P, Spiegel S, et al. (2010) Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis. J Cell Physiol 222:546-555.
38. Sauane M, Su ZZ, Gupta P, Lebedeva IV, Dent P, Sarkar D, and Fisher PB (2008) Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proc Natl Acad Sci USA 105:9763-9768. (Pubitemid 352031374)
39. Su Z, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P, James CD, Randolph A, Valerie K, Walter MR, Dent P, and Fisher PB (2005) Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 24:7552-7566. (Pubitemid 41638030)
40. Su Z, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, Reed JC, Dent P, and Fisher PB (2001) A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 98:10332-10337. (Pubitemid 32803020)
41. Su ZZ, Lebedeva IV, Sarkar D, Emdad L, Gupta P, Kitada S, Dent P, Reed JC, and Fisher PB (2006) Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2. Oncogene 25:2339-2348.
42. Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC, Goldstein NI, and Fisher PB (1998) The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci USA 95:14400-14405. (Pubitemid 28549379)
43. Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, and Giaccia AJ (2008) A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14:90-102. (Pubitemid 351885499)
44. Yacoub A, Gupta P, Park MA, Rhamani M, Hamed H, Hanna D, Zhang G, Sarkar D, Lebedeva IV, Emdad L, et al. (2008a) Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling. Mol Cancer Ther 7:314-329. (Pubitemid 351302525)
45. Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, Ogretmen B, Dash R, Sarkar D, Broaddus WC, et al. (2010) PKR endoplasmic reticulum kinase dependent regulation of ceramide synthase 6 and thioredoxin controls melanoma differentiation associated gene-7 glioma cell killing. Cancer Res 70:1120-1129.
46. Yacoub A, Mitchell C, Brannon J, Rosenberg E, Qiao L, McKinstry R, Linehan WM, Su ZS, Sarkar D, Lebedeva IV, et al. (2003) MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity. Mol Cancer Ther 2:623-632.
47. Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, Hanna D, Sarkar D, Lebedeva IV, Emdad L, et al. (2008b) Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther 7:297-313. (Pubitemid 351302524)
48. Zhou GB, Zhang J, Wang ZY, Chen SJ, and Chen Z (2007) Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci 362:959-971. (Pubitemid 47056795)